Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Head And Neck Cancer (HNC) Market Size Changed, over the years?

Recent years have seen a robust growth in the head and neck cancer (HNC) market. The market value is forecasted to rise from $2.00 billion in 2024 to $2.17 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.2%. A few contributing factors to the growth seen in the historic period include an uptick in HPV-related cancer incidents, heightened smoking and alcohol usage, escalated investment in cancer research, improved awareness leading to early detection, and a rise in the aging population.

How Much Will the Head And Neck Cancer (HNC) Market Be Worth in 2029?

The head and neck cancer (HNC) market is anticipated to witness a significant surge in the forthcoming years, reaching $2.93 billion in 2029 with a compound annual growth rate (CAGR) of 7.8%. This robust growth during the forecast period can be credited to factors such as the expansion of healthcare infrastructure, increase in patient numbers, an ageing population, escalating healthcare costs, and the widespread prevalence of tobacco usage and alcohol intake. Key trends that will dominate the forecast period include advancements in immunotherapy, targeted therapies, the merging of technology, the incorporation of artificial intelligence (AI), and the evolution of precision medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20825&type=smp

Which is the Largest Company in the Head And Neck Cancer (HNC) Market?

Major companies operating in the head and neck cancer (HNC) market are Pfizer Inc., Siemens Healthcare Private Limited, F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Healthcare AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Koninklijke Philips N.V., Boehringer Ingelheim, Fresenius Kabi AG, Incyte Corporation, Exelixis Inc., Astellas Pharma Inc., Rakuten Medical Inc., Merus N.V.

What Are the Main Market Drivers in the Head And Neck Cancer (HNC) Industry?

The surge in cigarette smoking incidents is anticipated to drive the expansion of the head and neck cancer (HNC) market. Cigarette smoking, which involves inhaling and exhaling smoke from burnt tobacco in cigarettes, carries associated health risks and addiction. The rise in cigarette smoking instances can be correlated to factors such as stress, societal influences, assertive advertising, and the availability of tobacco products. Drugs for head and neck cancers can counter the adverse effects of cigarette smoking by targeting the molecular changes caused by smoking and treating cancers related to tobacco consumption. These drugs also highlight the importance of decreasing exposure to carcinogens related to smoking for improved treatment results. For example, a study conducted by the European Respiratory Society (ERS), a non-profit organization based in Switzerland, highlighted an alarming increase in smoking rates among youth in October 2024, with the percentage of respondents who smoked climbing from 22.5% in 2022 to 40.1% in 2024. Thus, the rising frequency of cigarette smoking is contributing to the growth of the head and neck cancer (HNC) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20825&type=smp

How Is the Head And Neck Cancer (HNC) Market Segments Structured?

The head and neck cancer (HNC) market covered in this report is segmented –

1) By Type: Laryngeal Cancer, Pharyngeal Cancer, Salivary Gland Cancer, Lip And Oral Cavity Cancer, Nasopharyngeal Cancer, Other Types

2) By Treatment: Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy, Other Treatments

3) By Diagnosis: Bioscopy Screening Tests, Blood Tests, Dental Diagnosis, Imaging, Endoscopy

4) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, E-commerce

5) By End User: Hospital, Specialty Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Laryngeal Cancer: Supraglottic Laryngeal Cancer, Glottic Laryngeal Cancer, Subglottic Laryngeal Cancer

2) By Pharyngeal Cancer: Oropharyngeal Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer

3) By Salivary Gland Cancer: Parotid Gland Cancer, Sublingual Gland Cancer, Submandibular Gland Cancer, Minor Salivary Gland Cancer

4) By Lip And Oral Cavity Cancer: Lip Cancer, Buccal Mucosa Cancer, Tongue Cancer, Gingival Cancer, Palate Cancer

5) By Nasopharyngeal Cancer: Early-Stage Nasopharyngeal Cancer, Advanced-Stage Nasopharyngeal Cancer

6) By Other Types: Thyroid Cancer, Esophageal Cancer, Sinonasal Cancer

What Strategic Trends Are Transforming the Head And Neck Cancer (HNC) Market?

Leading companies in the head and neck cancer (HNC) market are concentrating on the creation of new formulations such as immune oncology drugs. The goal is to improve treatment effectiveness, raise patient survival rates, and provide solutions for unmet medical requirements in handling sophisticated and advanced-stage cancers. Immuno-oncology drugs are therapies that utilise the body’s immunity to identify and combat cancerous cells. They range from checkpoint inhibitors and CAR-T cell therapies to cancer vaccines. For instance, Dr. Reddy’s Laboratories from India introduced an immune oncology drug known as toripalimab in November 2024. This medicine, designed for adults suffering from an unusual form of head and neck cancer that begins in the nasopharynx (upper throat area), is specifically for recurrent or metastatic nasopharyngeal carcinoma treatment. The drug will be sold under the brand name Zytorvi. When used with standard chemotherapy (gemcitabine and cisplatin), the medicine indicated a 48% decrease in progression risk or death.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/head-and-neck-cancer-hnc-global-market-report

Which Global Regions Offer the Highest Growth in the Head And Neck Cancer (HNC) Market?

North America was the largest region in the head and neck cancer (HNC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer (HNC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20825

This Report Delivers Insight On:

1. How big is the head and neck cancer (hnc) market, and how is it changing globally?

2. Who are the major companies in the head and neck cancer (hnc) market, and how are they performing?

3. What are the key opportunities and risks in the head and neck cancer (hnc) market right now?

4. Which products or customer segments are growing the most in the head and neck cancer (hnc) market?

5. What factors are helping or slowing down the growth of the head and neck cancer (hnc) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model